| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, ... New England journal of medicine 344 (11), 783-792, 2001 | 14030 | 2001 |
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, ... Journal of clinical oncology 25 (33), 5287-5312, 2007 | 3311 | 2007 |
| The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial SR Cummings, S Eckert, KA Krueger, D Grady, TJ Powles, JA Cauley, ... Jama 281 (23), 2189-2197, 1999 | 2563 | 1999 |
| A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, ... New England Journal of Medicine 349 (19), 1793-1802, 2003 | 2422 | 2003 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2200 | 2012 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2159 | 1998 |
| Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive … ML Citron, DA Berry, C Cirrincione, C Hudis, EP Winer, WJ Gradishar, ... Journal of clinical oncology 21 (8), 1431-1439, 2003 | 2069 | 2003 |
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Baselga, D Tripathy, J Mendelsohn, S Baughman, CC Benz, L Dantis, ... Journal of clinical oncology 14 (3), 737-744, 1996 | 1965 | 1996 |
| The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress RK Portenoy, HT Thaler, AB Kornblith, JMC Lepore, H Friedlander-Klar, ... european Journal of cancer 30 (9), 1326-1336, 1994 | 1816 | 1994 |
| Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast … IC Henderson, DA Berry, GD Demetri, CT Cirrincione, LJ Goldstein, ... Journal of clinical oncology 21 (6), 976-983, 2003 | 1731 | 2003 |
| Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation ND Kauff, JM Satagopan, ME Robson, L Scheuer, M Hensley, CA Hudis, ... New England Journal of Medicine 346 (21), 1609-1615, 2002 | 1666 | 2002 |
| Tumor self-seeding by circulating cancer cells MY Kim, T Oskarsson, S Acharyya, DX Nguyen, XHF Zhang, L Norton, ... Cell 139 (7), 1315-1326, 2009 | 1565 | 2009 |
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17 PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, ... Journal of the National Cancer Institute 97 (17), 1262-1271, 2005 | 1465 | 2005 |
| Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing … J Baselga, L Norton, J Albanell, YM Kim, J Mendelsohn Cancer research 58 (13), 2825-2831, 1998 | 1460 | 1998 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1228 | 2018 |
| Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis RB Hazan, GR Phillips, RF Qiao, L Norton, SA Aaronson The Journal of cell biology 148 (4), 779-790, 2000 | 1209 | 2000 |
| Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer KS Hughes, LA Schnaper, D Berry, C Cirrincione, B McCormick, B Shank, ... New England Journal of Medicine 351 (10), 971-977, 2004 | 1191 | 2004 |
| A CXCL1 paracrine network links cancer chemoresistance and metastasis S Acharyya, T Oskarsson, S Vanharanta, S Malladi, J Kim, PG Morris, ... Cell 150 (1), 165-178, 2012 | 1124 | 2012 |
| SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN. 2. O Abe, R Abe, K Asaishi, K Enomoto, T Hattori, Y Ino, K Kikuchi, ... Lancet 339 (8785), 71-85, 1992 | 1090 | 1992 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1028 | 2020 |
